videoSlug

VideoSlug_VideoQuery

slug

VideoPageContentQuery

content

videos

query VideoSlug_VideoQuery(
  $videoSlug: String!
) {
  ...VideoPageContentQuery_1X4EH4
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment LatestVideos_Videos on Query {
  videos(first: 5, upcoming: false, order: {field: liveTime, direction: DESC}) {
    edges {
      node {
        id
        title
        lang
        pageUrl
        liveTime
        isLive
        companies {
          name
          squareLogoUrl
          id
        }
      }
    }
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment VideoPageContentQuery_1X4EH4 on Query {
  content(slug: $videoSlug, type: [VIDEO, WEBCAST]) {
    __typename
    id
    title
    slug
    lang
    htmlBody
    companies {
      viewerIsFollowing
      id
      name
      pageUrl
      defaultInstrument {
        id
        isin
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    createdAt
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    ... on Video {
      imgUrl
      videoEmbedUrl(location: "inderes")
      audioEmbedUrl
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ... on Webcast {
      imgUrl
      videoEmbedUrl(location: "inderes")
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
  }
  ...LatestVideos_Videos
}


type

__typename

title

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

first

order

upcoming

edges

Ascelia Pharma

Ascelia Pharma is expected to release its Q3 2025 interim report on 5 November 2025. Join us for a live presentation with Deputy CEO Julie Waras Brogren from Ascelia Pharma the following day at 12:00 PM CET, where she will present the financial results for the first nine months of 2025. Participants will have the opportunity to ask questions and gain insights into the company’s latest developments.

You can already sign up for the event and submit your questions. You don&#x2019;t need to attend live to send in your questions for the presentation. Ascelia Pharma is expected to release its Q3 2025 interim report on 5 November 2025. Join us for a live presentation with Deputy CEO Julie Waras Brogren from Ascelia Pharma the following day at 12:00 PM CET, where she will present the financial results for the first nine months of 2025. Participants will have the opportunity to ask questions and gain insights into the company&#x2019;s latest developments. Since the release of the H1 2025 results, the company has reached one of this year&#x2019;s key milestones with the submission of the NDA for Orviglance. Furthermore, Ascelia Pharma has completed a directed share issue raising approximately SEK 30 million, extending its cash runway into Q4 2026, beyond the expected timeline for the FDA response, and thereby de-risking the near-term funding outlook. In addition to the financial results, the presentation is expected to include a discussion on upcoming partnering activities related to Orviglance, which could represent the next major trigger for the company. About Ascelia Pharma Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. Ascelia Pharma has two drug candidates in clinical development &#x2013; Orviglance&#xae; (Mangoral) and Oncoral. The company is headquartered in Malm&#xf6;, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement / Michael Friis, 09.00 AM CET, 14 October 2025.

Ascelia Pharma – Presentation of interim Q3 2025 report

Recent videos